SFOSF (SFOSF) Stock Price & Analysis
SFOSF (SFOSF) rose 0.00% to USD 2.2 as of July 25, 2026 at 14:25 UTC, according to Nexqual real-time market data.
SFOSF last closed at USD 2.2; the session ranged USD 2.2–2.2 on volume of 100 shares. Market capitalization is $8.28B, with a 52-week range of USD 2.02–3.5 (PNK). Source: Nexqual, July 25, 2026 at 14:25 UTC.
Key Statistics (as of July 25, 2026 at 14:25 UTC)
| Price | USD 2.2 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.2 |
| Open | USD 2.2 |
| Day Range | USD 2.2 – 2.2 |
| 52-Week Range | USD 2.02 – 3.5 |
| Volume | 100 shares |
| Market Cap | $8.28B |
| Exchange | PNK |
Technical Analysis (SFOSF)
Nexqual's technical model rates SFOSF "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 14:25 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 64.43 (neutral) |
| vs SMA50 | Above (USD 2.17) |
| MACD | 0.02 (positive) |
Analyst Ratings (SFOSF)
Wall Street analysts rate SFOSF "None", per Nexqual as of July 25, 2026 at 14:25 UTC.
| Consensus Rating | None |
|---|
Earnings (SFOSF)
| Revenue Estimate | $11.13B |
|---|
Source: Nexqual, July 25, 2026 at 14:25 UTC.
Financials & Fundamentals (SFOSF)
| Total Revenue | $42.31B |
|---|---|
| Revenue Growth (YoY) | +6.90% |
| Gross Margin | +50.31% |
| Operating Margin | +8.08% |
| Profit Margin | +8.22% |
| ROE | +7.04% |
| Debt / Equity | 62.09 |
| Current Ratio | 0.93 |
| Total Cash | $15.29B |
| Total Debt | $39.53B |
| Free Cash Flow | $-603.63M |
Source: Nexqual, July 25, 2026 at 14:25 UTC.
Financial Health Score (SFOSF)
Nexqual rates SFOSF's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 14:25 UTC.
| Growth | Mixed — Revenue +1.8% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 50%, operating 8% |
| Balance Sheet | Mixed — $15.3B cash vs $39.5B debt |
| Cash Flow | Weak — FCF negative: -$604M, burning cash |
| Efficiency | Mixed — ROE 7%, ROA 1.5% |
Ownership (SFOSF)
| Insider Ownership | +14.35% |
|---|---|
| Institutional Ownership | +24.41% |
| Shares Outstanding | 551.94M |
| Float | 1.63B |
Source: Nexqual, July 25, 2026 at 14:25 UTC.
Leadership (SFOSF)
SFOSF is led by Wang Xingli (age 63), Co-President & CEO of the Innovative Drugs Business Unit, per Nexqual as of July 25, 2026 at 14:25 UTC.
| Co-President & CEO of the Innovative Drugs Business Unit | Wang Xingli (age 63) |
|---|---|
| Executive Co-Chairman | Xiaohui Guan (age 54) |
| Executive Chairman | Yuqing Chen (age 50) |
| Executive Vice Chairman | Deyong Wen (age 54) |
| Executive President & Chief Human Resources Officer | Rongli Feng (age 50) |
Major Backers & Investors (SFOSF)
Notable institutional backers of SFOSF include DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT., Roundhill ETF Trust-Roundhill GLP-1 & Weight Loss ETF, according to Nexqual as of July 25, 2026 at 14:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT. | 0.49% |
| Roundhill ETF Trust-Roundhill GLP-1 & Weight Loss ETF | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.68% |
| Dimensional Fund Advisors | 0.32% |
Source: Nexqual, July 25, 2026 at 14:25 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OPHLY | Ono Pharmaceutical Co., Ltd. | USD 4.93 | ▲ 1.65% |
| SGIOY | Shionogi & Co. Ltd. | USD 8.68 | ▼ 0.8% |
| SBMFF | SINO BIOPHARMACEUTICAL | USD 0.64 | ▲ 0% |
| SHTDY | Sinopharm Group Co. Ltd. | USD 10.73 | ▼ 0.89% |
| SGIOF | Shionogi & Co. Ltd. | USD 17.45 | ▼ 0.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 14:25 UTC. This page is informational and not investment advice.